EMERYVILLE, Calif. (August 30, 2018) – NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 2:35 p.m. Eastern time (5:35 p.m. Pacific time). The conference is being held at the St. Regis New York in New York City.
A live webcast and replay will be available on the Investors section of the Company’s website at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
For NovaBay Avenova purchasing information:
Please Call us toll free: 1-800-890-0329 or email email@example.com
From the Company
Chief Financial Officer